OPKO Health (OPK) Stock Forecast, Price Target & Predictions
OPK Stock Forecast
OPKO Health stock forecast is as follows: an average price target of $3.00 (represents a 94.81% upside from OPK’s last price of $1.54) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
OPK Price Target
The average price target for OPKO Health (OPK) is $3.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 94.81% upside from OPK's last price of $1.54.
OPK Analyst Ratings
According to 10 Wall Street analysts, OPKO Health's rating consensus is 'Buy'. The analyst rating breakdown for OPK stock is 0 'Strong Buy' (0.00%), 5 'Buy' (50.00%), 5 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
OPKO Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | Yi Chen | H.C. Wainwright | $3.00 | $1.70 | 76.99% | 94.81% |
| Dec 15, 2022 | H.C. Wainwright | $3.00 | $1.29 | 132.56% | 94.81% | |
| Aug 04, 2022 | Edward Tenthoff | Piper Sandler | $4.00 | $2.40 | 66.67% | 159.74% |
The latest OPKO Health stock forecast, released on Sep 17, 2024 by Yi Chen from H.C. Wainwright, set a price target of $3.00, which represents a 76.99% increase from the stock price at the time of the forecast ($1.70), and a 94.81% increase from OPK last price ($1.54).
OPKO Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $1.54 | $1.54 | $1.54 |
| Upside/Downside | -100.00% | -100.00% | 94.81% |
In the current month, the average price target of OPKO Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OPKO Health's last price of $1.54. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 17, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 17, 2024 | New Street | Buy | Buy | Hold |
| Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 01, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 29, 2023 | JMP Securities | Market Perform | Initialise | |
| Jun 29, 2023 | Guggenheim | Neutral | Initialise | |
| Jun 29, 2023 | Susquehanna | Positive | Upgrade | |
| Jun 29, 2023 | Piper Sandler | Overweight | Neutral | Upgrade |
| Jun 29, 2023 | UBS | Neutral | Downgrade | |
| Jun 29, 2023 | Citigroup | Neutral | Downgrade | |
| Aug 04, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | Hold | Downgrade |
OPKO Health's last stock rating was published by Sandler O'Neill on Sep 17, 2024. The company gave OPK a "Buy" rating, the same as its previous rate.
OPKO Health Financial Forecast
OPKO Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $181.88M | $178.59M | $265.42M | $237.60M | $185.40M | $179.74M | $309.89M | $329.22M | $401.33M | $385.81M | $442.41M | $545.16M | $494.67M | $428.06M | $301.21M | $211.47M | $224.34M | $228.77M |
| Avg Forecast | $178.80M | $167.80M | $170.40M | $166.60M | $174.93M | $166.38M | $162.60M | $156.38M | $155.42M | $181.52M | $184.70M | $182.99M | $177.53M | $174.78M | $201.97M | $193.35M | $168.21M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| High Forecast | $182.31M | $171.09M | $173.75M | $169.87M | $178.36M | $169.64M | $165.79M | $160.50M | $156.78M | $181.52M | $188.33M | $182.99M | $179.18M | $174.78M | $205.94M | $197.15M | $171.51M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| Low Forecast | $173.47M | $162.80M | $165.32M | $161.64M | $169.71M | $161.42M | $157.76M | $149.57M | $152.77M | $181.52M | $179.20M | $182.99M | $175.90M | $174.78M | $195.95M | $187.59M | $163.20M | $183.51M | $326.87M | $332.62M | $329.83M | $302.27M | $456.36M | $494.16M | $443.10M | $378.66M | $245.60M | $218.00M | $216.07M | $225.40M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.31% | 1.23% | 1.10% | 0.98% | 0.95% | 0.99% | 1.22% | 1.28% | 0.97% | 1.10% | 1.12% | 1.13% | 1.23% | 0.97% | 1.04% | 1.01% |
OPKO Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $182.99M, with a low forecast of $182.99M, and a high forecast of $182.99M. OPK's average Quarter revenue forecast represents a 0.61% increase compared to the company's last Quarter revenue of $181.88M (Dec 23).
OPKO Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-161.06M | $-64.41M | $13.20M | $-8.90M | $-41.30M | $-98.17M | $-70.77M | $-46.15M | $-42.78M | $54.67M | $14.03M | $57.02M | $71.38M | $47.06M | $67.47M | $-30.41M | $-80.93M | $-30.64M |
| Avg Forecast | $-14.73M | $-13.82M | $-14.04M | $-13.72M | $-14.41M | $-13.70M | $-13.39M | $-12.88M | $-12.80M | $-14.95M | $-15.21M | $-37.29M | $-14.62M | $-14.40M | $-16.64M | $-33.90M | $-148.23M | $-8.20M | $-14.61M | $-30.82M | $-14.74M | $-13.51M | $-20.40M | $57.02M | $-19.80M | $-16.92M | $-10.98M | $-30.41M | $-9.66M | $-10.07M |
| High Forecast | $-14.29M | $-13.41M | $-13.62M | $-13.31M | $-13.98M | $-13.30M | $-12.99M | $-12.32M | $-12.58M | $-14.95M | $-14.76M | $-29.83M | $-14.49M | $-14.40M | $-16.14M | $-27.12M | $-118.58M | $-8.20M | $-14.61M | $-24.65M | $-14.74M | $-13.51M | $-20.40M | $68.43M | $-19.80M | $-16.92M | $-10.98M | $-24.33M | $-9.66M | $-10.07M |
| Low Forecast | $-15.02M | $-14.09M | $-14.31M | $-13.99M | $-14.69M | $-13.97M | $-13.66M | $-13.22M | $-12.91M | $-14.95M | $-15.51M | $-44.74M | $-14.76M | $-14.40M | $-16.96M | $-40.68M | $-177.88M | $-8.20M | $-14.61M | $-36.98M | $-14.74M | $-13.51M | $-20.40M | $45.62M | $-19.80M | $-16.92M | $-10.98M | $-36.50M | $-9.66M | $-10.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 11.01% | 4.47% | -0.79% | 0.26% | 0.28% | 11.97% | 4.84% | 1.50% | 2.90% | -4.05% | -0.69% | 1.00% | -3.60% | -2.78% | -6.15% | 1.00% | 8.38% | 3.04% |
4 analysts predict OPK's average Quarter EBITDA for Sep 23 to be $-14.40M, with a high of $-14.40M and a low of $-14.40M. This is -209.08% lower than OPKO Health's previous annual EBITDA (Jun 23) of $13.20M.
OPKO Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-66.52M | $-84.47M | $-19.64M | $-18.20M | $-85.20M | $-86.05M | $-101.38M | $-55.38M | $-73.31M | $28.74M | $-16.19M | $31.08M | $32.30M | $23.72M | $33.70M | $-59.13M | $-112.35M | $-62.01M |
| Avg Forecast | $-49.92M | $-59.90M | $-59.90M | $-59.90M | $-67.39M | $-69.89M | $-72.38M | $-77.37M | $-79.87M | $-93.18M | $-94.84M | $-44.72M | $-99.84M | $-99.84M | $-71.55M | $-40.65M | $-255.63M | $-58.57M | $5.58M | $-36.96M | $-13.94M | $-6.97M | $12.55M | $31.08M | $29.28M | $30.68M | $-46.02M | $-59.13M | $-61.01M | $-62.75M |
| High Forecast | $-47.99M | $-57.58M | $-57.58M | $-57.58M | $-64.78M | $-67.18M | $-69.58M | $-38.69M | $-26.62M | $-89.57M | $-91.17M | $-35.77M | $-88.74M | $-95.97M | $-68.78M | $-32.52M | $-204.50M | $-58.57M | $5.58M | $-29.56M | $-13.94M | $-6.97M | $12.55M | $37.29M | $29.28M | $30.68M | $-46.02M | $-47.31M | $-61.01M | $-62.75M |
| Low Forecast | $-51.19M | $-61.43M | $-61.43M | $-61.43M | $-69.11M | $-71.67M | $-74.23M | $-116.06M | $-133.11M | $-95.56M | $-97.27M | $-53.66M | $-110.93M | $-102.38M | $-73.38M | $-48.78M | $-306.75M | $-58.57M | $5.58M | $-44.35M | $-13.94M | $-6.97M | $12.55M | $24.86M | $29.28M | $30.68M | $-46.02M | $-70.96M | $-61.01M | $-62.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 0.85% | 0.27% | 0.45% | 0.33% | 1.47% | -18.18% | 1.50% | 5.26% | -4.12% | -1.29% | 1.00% | 1.10% | 0.77% | -0.73% | 1.00% | 1.84% | 0.99% |
OPKO Health's average Quarter net income forecast for Dec 21 is $-13.94M, with a range of $-13.94M to $-13.94M. OPK's average Quarter net income forecast represents a -148.52% decrease compared to the company's last Quarter net income of $28.74M (Sep 21).
OPKO Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $72.77M | $72.24M | $79.79M | $75.70M | $74.00M | $79.67M | $101.46M | $117.54M | $138.21M | $105.12M | $113.24M | $112.29M | $101.82M | $99.90M | $77.72M | $76.13M | $79.13M | $80.54M |
| Avg Forecast | $57.64M | $54.09M | $54.93M | $53.71M | $56.39M | $53.63M | $52.42M | $50.41M | $50.10M | $58.52M | $59.54M | $94.81M | $57.23M | $56.34M | $65.11M | $86.19M | $54.22M | $59.16M | $105.37M | $78.36M | $106.32M | $97.44M | $147.11M | $112.29M | $142.84M | $122.07M | $79.17M | $76.13M | $69.65M | $72.66M |
| High Forecast | $58.77M | $55.15M | $56.01M | $54.76M | $57.50M | $54.69M | $53.44M | $51.74M | $50.54M | $58.52M | $60.71M | $113.78M | $57.76M | $56.34M | $66.39M | $103.43M | $55.29M | $59.16M | $105.37M | $94.03M | $106.32M | $97.44M | $147.11M | $134.74M | $142.84M | $122.07M | $79.17M | $91.36M | $69.65M | $72.66M |
| Low Forecast | $55.92M | $52.48M | $53.29M | $52.11M | $54.71M | $52.04M | $50.85M | $48.21M | $49.25M | $58.52M | $57.77M | $75.85M | $56.70M | $56.34M | $63.17M | $68.96M | $52.61M | $59.16M | $105.37M | $62.69M | $106.32M | $97.44M | $147.11M | $89.83M | $142.84M | $122.07M | $79.17M | $60.91M | $69.65M | $72.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.27% | 1.28% | 1.23% | 0.88% | 1.36% | 1.35% | 0.96% | 1.50% | 1.30% | 1.08% | 0.77% | 1.00% | 0.71% | 0.82% | 0.98% | 1.00% | 1.14% | 1.11% |
OPKO Health's average Quarter SG&A projection for Mar 24 is $94.81M, based on 4 Wall Street analysts, with a range of $75.85M to $113.78M. The forecast indicates a 30.30% rise compared to OPK last annual SG&A of $72.77M (Dec 23).
OPKO Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 13 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-8.85 | $-0.11 | $-0.03 | $-0.02 | $-0.11 | $-0.11 | $-0.14 | $-0.08 | $-0.11 | $0.04 | $-0.03 | $0.05 | $0.05 | $0.04 | $0.05 | $-0.09 | $-0.18 | $-0.11 |
| Avg Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.08 | $-0.08 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.07 | $-0.08 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| High Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.04 | $-0.03 | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.10 | $-0.07 | $-0.07 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| Low Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.07 | $-0.12 | $-0.13 | $-0.10 | $-0.10 | $-0.10 | $-0.11 | $-0.10 | $-0.07 | $-0.08 | $-0.11 | $-0.08 | $0.01 | $-0.06 | $-0.02 | $-0.01 | $0.02 | $0.05 | $0.04 | $0.04 | $-0.07 | $-0.09 | $-0.09 | $-0.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 88.50% | 1.10% | 0.36% | 0.32% | 0.99% | 1.31% | -17.50% | 1.50% | 5.50% | -4.00% | -1.67% | 1.04% | 1.19% | 0.91% | -0.76% | 1.03% | 2.06% | 1.22% |
According to 4 Wall Street analysts, OPKO Health's projected average Quarter EPS for Dec 21 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -150.00% decrease compared to OPK previous annual EPS of $0.04 (Sep 21).
OPKO Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TTOO | T2 Biosystems | $0.34 | $5.00 | 1370.59% | Hold |
| FLGT | Fulgent Genetics | $19.44 | $45.00 | 131.48% | Buy |
| BDSX | Biodesix | $1.39 | $3.00 | 115.83% | Buy |
| OPK | OPKO Health | $1.61 | $3.00 | 86.34% | Buy |
| CDNA | CareDx | $22.14 | $37.50 | 69.38% | Buy |
| CSTL | Castle Biosciences | $28.14 | $40.50 | 43.92% | Buy |
| IDXX | IDEXX Laboratories | $427.09 | $510.00 | 19.41% | Buy |
| GH | Guardant Health | $34.84 | $40.60 | 16.53% | Buy |
| A | Agilent | $136.46 | $147.40 | 8.02% | Buy |
| ILMN | Illumina | $143.12 | $147.78 | 3.26% | Buy |
| TWST | Twist Bioscience | $48.40 | $46.00 | -4.96% | Buy |
| NTRA | Natera | $168.21 | $151.50 | -9.93% | Buy |
| ME | 23andMe | $3.24 | $0.42 | -87.04% | Buy |